AIM ImmunoTech Inc. (AIM) has seen some recent action in the marketplace and its common shares closed trading at $1.9800 yesterday. People are starting to take notice of AIM as the common shares traded as high as $2.0500 and as low as $1.9600 in the previous market trading session.
AIM ImmunoTech Inc. (AIM) average trading volume is 8.97M. However, in the previous market trading session AIM ImmunoTech Inc. (AIM) traded 950,092 shares. The first downside support level on AIM is $1.32 and the first upside resistance level on AIM is $6.10. AIM 50day moving average is $2.2969 and AIM 200day moving average is $1.2810.
AIM ImmunoTech Inc. (AIM) recent performance has been indicated by the recent movement in AIM common shares. AIM has performed -30.53% over the past month, AIM has performed 85.05% over the past 90 days and AIM has shown -73.36% over the past 12 months. AIM ImmunoTech Inc. (AIM) has a 1 year range of $0.3800 to $7.5000. AIM ImmunoTech Inc. (AIM) is trading 419.69% from its 1 year low and -76.79% from its 1 year high. AIM ImmunoTech Inc. (AIM) is displaying a 2.50% short float displaying the quantity short in the float.
AIM has 28.47M shares outstanding and 27.07M shares in the float. AIM ImmunoTech Inc. (AIM) presently has a market cap of $56.37M and income of $-9.50M. The EPS next quarter for AIM is -0.15 and projected EPS net year is 9.80%. The market cap of AIM ImmunoTech Inc. (AIM) at $56.37M represents how many People own shares of AIM and is based off the last price ($1.9800) of AIM and the quantity of shares outstanding (28.47M) with AIM ImmunoTech Inc. (AIM).
AIM ImmunoTech Inc. (AIM) has aggregate cash (mrq) of 8.78M, aggregate cash per share (mrq) of 0.32, aggregate debt of AIM stands at 6.38M and aggregate debt/equity (mrq) is 49.43. AIM ImmunoTech Inc. (AIM) operational cash flow (ttm) is -9.07M and AIM leveraged free cash flow (ttm) is -6.93M.
AIM is trading -12.02% below (bearish) its SMA20, -17.36% below (bearish) its SMA50 and 39.54% above (bullish) its SMA200.
In recent news, on April 29, 2020, it was announced, AIM ImmunoTech’s CEO to Present at Maxim’s Infectious Disease Virtual Conference. In this news it stated, OCALA, FL . AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that CEO Thomas K. Equels is scheduled to present at Maxim’s Infectious Disease Virtual Conference to be held on May 5, 2020. Mr. Equels will discuss the urgent need for a therapeutic and vaccine for COVID-19 and give a brief overview of Ampligen® and its current and potential indications. Panel Discussion Details:
About AIM ImmunoTech Inc. (AIM):
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases.